Transforming Discovery into Opportunity

Antibiotic resistance is a major world-wide health problem that is threatening our ability to treat common infectious diseases. CDRD is collaborating with UK partners LifeArc and the Defence Science and Technology Laboratory (Dstl), to ID antibacterial drug targets in the fight against antibiotic resistance.

Details here…

Sitka Biopharma Inc., a spin-off of CDRD & the University of British Columbia (UBC) has partnered with a major UK cancer centre to advance Sitka’s bladder cancer treatment into an early phase clinical trial.

Read more…

CDRD & Aequus are collaborating & sharing respective expertise that could lead to new cannabinoid therapeutics and a pathway to clinical trials, particularly in neurological movement disorders.

Additional info…

Novelogics Biotechnology, Inc. & CDRD are collaborating to further characterize Novelogics’ internally-developed antibody immunotherapy for treating cancer.

More details here…

Dr. Philippe Séguéla from the Montreal Neurological Institute has been selected to work with CDRD to further develop his progressive MS translational project focused on blocking specific ion channels in the brain.

Read more about Dr. Séguéla’s research…

Meet Amber, Katrina from Pigeon Lake, AB, Lucas from Rorketon, MB and Destiny from Gift Lake, AB who have joined the CDRD team in our Target Validation and Analytical Chemistry divisions from May 15-19.

More about our special guests here…

CDRD is a partner in one of 16 new collaborative research projects announced by BioCanRx. These projects are aimed at finding improved treatment options and outcomes for cancer patients and  developing clinical Chimeric Antigen Receptor modified T cell (CAR-T) manufacturing capabilities in Canada.

Find out how…

Health sciences researchers, entrepreneurs, and companies alike have the opportunity to collaborate with CDRD and thereby access its full suite of expertise, infrastructure, and broad partnerships and networks.

Find out how CDRD supports Canadian Small/Medium Enterprises (SMEs)……

CDRD BY THE NUMBERS:

  • Over 1,100 early-stage technologies evaluated for commercial potential
  • Over 200 projects on 134 distinct technologies
  • 56 technologies advanced toward commercialization and/or commercialized
  • 7 spin-off companies launched
  • 14 technologies out-licensed

What is CDRD?

Headquartered in Vancouver, British Columbia, The Centre for Drug Research and Development (CDRD) is Canada’s national drug development and commercialization engine.

We work in partnership with academia, industry, government and foundations, to provide the specialized expertise and infrastructure to identify and de-risk promising discoveries generated by health-related research, and transform them into commercially viable investment opportunities for the private sector – and ultimately into innovative new therapies for patients.

In doing so, CDRD is actively growing our national health sciences industry into a wholly-optimized generator of economic prosperity for the country.

Since 2008, Canada’s Networks of Centres of Excellence Program has recognized CDRD as a Centre of Excellence for Commercialization and Research (CECR).

Latest from the Blog

Help Bring Canadian Research into the Marketplace

CDRD part of $1.5 million project with MNI to advance new treatments for Parkinson’s Disease

+ VISIT THE BLOG

Latest from Twitter


+ FOLLOW US ON TWITTER



A Shared Vision










  • Industry
  • Academia
  • Government

Sign up to our newsletter

Receive CDRD's e-newsletter, The CDRD Pipeline and other e-communications for regular updates on all our news and activities.



© Copyright 2017 CDRD. All rights reserved.

>